Navigation Links
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Date:1/4/2012

three months of follow up, for which historical data are available, the percentage of patients gaining three or more lines was 50-55% in both dosing cohorts. These values are higher than historical data reported in two different published clinical studies exploring the natural course of the disease where only 39 or 20% of patients, respectively, gained 3 or more lines at 3 months after disease onset(1). In the latter case, the advantages of treatment with QPI-1007 were strongly significant. Furthermore, at 1 month after the administration of QPI-1007, patients gained on average 13 and 16 letters in the two dose groups. At 3 months, average letter gain was 14 in both groups and none of the patients lost vision compared to screening data.  A change of 15 letters is considered to be a substantial improvement in visual acuity. Evaluation of these patients is ongoing, with additional assessments planned at six- and 12-months post-injection.

"We are very encouraged by these interim clinical data. The data suggest that QPI-1007 may improve visual acuity in NAION patients.  Based on the interim data from this clinical study, and from our positive results from preclinical studies in three different models of optic neuropathy, including a model of glaucoma, we believe QPI-1007 may protect neurons in the retina and optic nerve in NAION and in other types of optic neuropathy, the most common of which is glaucoma," said Dr. Daniel Zurr, Quark's Chief Executive Officer. "QPI-1007 represents Quark's first drug with proprietary RNAi structure, and we believe these interim results support our position as a world leader in the discovery and development of RNAi-based therapeutics."

About NAION

Non-arteritic ischemic optic neuropathy (NAION) is the most common cause of sudden optic nerve-related vision loss. NAION is an acute ischemic disorder believed to be caused by insufficient arterial blood flow to the optic nerve via the posterior c
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -   The issue: ... tests confirmed it contains two undeclared amphetamine-like drug substances ... distributor, Empire Health Distribution of Terrebonne, Quebec ... across Canada .  Jetfuel Superburn is ... and increased energy. What consumers should ...
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... and Pipeline Analysis, 4th Edition Now Available... -- DALLAS, September 28, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... SCOLR Pharma, Inc. (NYSE AMEX: DDD ... as the Chairman of its Board of Directors.  Johnson ... the Board.   Johnson previously served as ... Under Johnson,s leadership, Matrixx successfully developed and launched the ...
Cached Medicine Technology:Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 2Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 3Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 4Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 5Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 6Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 7Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 8Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 9SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 2SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 3
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... Dynavax Technologies,Corporation (Nasdaq: DVAX ) announced today ... present an overview of the,company at two investor conferences ... will present at the CIBC World Markets 18th Annual,Healthcare ... ET (5:35,a.m. PT). In addition, Ostrach will present at ...
... Inc. today,announced the initiation of a phase 1 ... treatment of hypertension. AR9281 is a "first-in-class,",orally-active inhibitor ... the treatment of hypertension. The trial will enroll ... the safety, tolerability,pharmacokinetics and pharmacodynamics for single ascending ...
... Nov. 1 Amira Pharmaceuticals, Inc. announced,completion of ... Amira,s,internally discovered oral drug candidate for the treatment ... also announced the start,of a Phase 1 trial ... targets the,same inflammatory response. AM103 and AM803 ...
... NAPLES, Fla., Nov. 1 MediaBrains Inc., a ... http://www.agingcare.com . The,website will focus on the needs ... for connecting caregivers with expert information,resources, products and ... Month. The caregiver market represents one of ...
... 1, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the,global ... Q3 2007 Financial Highlights - Product sales up 41% ... $608.7 million; - Net cash provided by operating activities ... growth now expected to be at least 30% (Q2 guidance: ...
... - An Innovative Approach to Preventing Kidney Damage during ... ... Systems Inc. (Amex: PLC ), a,company focused on innovative cardiac ... RenalGuard,System(TM) during Renal Week, the American Society of Nephrology,s 40th,Annual Meeting ...
Cached Medicine News:Health News:Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Agingcare.com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30
Both versions of the UltraSling II provide immobilization for rotator cuff repairs, capusular shifts, Bankhart repairs, glenohumeral dislocations/subluxation and soft tissue repairs/strains....
Unique V-lock strapping system prevents roll and shifting to provide secure shoulder immobilization...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Effective spinal bracing is a critical component ... surgical stabilization. The Aspen® Lumbosacral Bracing System™ ... provide a high degree of immobilization, unparalled ... patients . . . even if they ...
Medicine Products: